Replies to post #189 on Dare Bioscience Inc (DARE)

[lecorb]

(NASDAQ:CERU) had its "buy" rating reaffirmed by analysts at Roth Capital. They now have a $2.50 price target on the stock. 164.7% upside from the previous close of $0.94.

http://www.americanbankingnews.com/2016/10/23/cerulean-pharma-inc-ceru-given-buy-rating-at-roth-capital.html